Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global
pharmaceutical company that specializes in the commercialization
and development of prescription ophthalmic pharmaceuticals for the
treatment of retinal diseases, today announced financial results
for the three months and year ended December 31, 2019. Alimera will
host a conference call on February 27, 2020, at 9:00 a.m. ET to
discuss these results.
“I am extremely proud to report record revenue for Alimera for
both the full year of 2019 and the recently completed fourth
quarter. Our international business exceeded our expectations
with overall revenue improving 49% year over year, driven by
organic growth, our expansion into France, and the launch of the
ILUVIEN® indication for uveitis in Germany and the United Kingdom
in the second half of the year.” said Rick Eiswirth, Alimera’s
President and Chief Executive Officer. “In the U.S. market, we
closed out the year with record quarterly end user demand for
ILUVIEN, a 14% increase over the fourth quarter of last year. We
are also pleased to have reached a significant milestone, having
achieved positive adjusted EBITDA for a full year for the first
time in the history of the company.”
Fourth Quarter and Full Year 2019 Financial
Results
Consolidated Net RevenueConsolidated net revenue increased 15%
to approximately $17.3 million for the three months ended December
31, 2019, compared to approximately $15.1 million for the three
months ended December 31, 2018.
For 2019, consolidated net revenue increased 16% to
approximately $53.9 million, compared to approximately $46.6
million in 2018.
U.S. Net RevenueU.S. net revenue grew 7% to approximately $9.5
million for three months ended December 31, 2019, compared to U.S.
net revenue of approximately $8.9 million for the three months
ended December 31, 2018. End user demand, which represents
units purchased by physicians and pharmacies from Alimera’s
distributors, increased 14% to 1,164 units compared to 1,019 units
during 2018.
The difference between GAAP revenue and end user demand is due
to the timing of distributor purchases from Q4 2019 versus Q4 2018.
During Q4 2018, Alimera's distributors purchased approximately 7%
more units than they sold to end users, increasing their stock on
hand during the quarter. During Q4 2019, Alimera's distributors
purchased approximately the same number of units that were sold to
end users.
For 2019, U.S. net revenue increased approximately $300,000 to
$32.3 million compared to $32.0 million in 2018. The increase was
primarily attributable to our increase in end user demand, which
increased 5% for the year ended December 31, 2019, increasing to
3,993 units compared to 3,802 units for the year ended December 31,
2018.
The difference between GAAP revenue and end user demand is due
to the timing of distributor purchases from quarter to quarter.
During 2018, Alimera’s distributors purchased approximately 3% more
units than they sold to end users, increasing their stock on hand
during that year. During 2019, Alimera’s distributors
purchased approximately 1% fewer units than they sold to end users,
decreasing their stock on hand during that year.
International Net RevenueNet revenues from Alimera’s
international segment increased 26% to approximately
$7.8 million for the three months ended December 31, 2019,
compared to approximately $6.2 million for the three months
ended December 31, 2018. The increase in international net revenue
in the fourth quarter of 2019 was primarily due to increased sales
in our international markets where we sell to distributors.
International net revenue increased 49% to approximately $21.7
million for 2019, compared to approximately $14.6 million in 2018.
The growth of revenue in the international segment was primarily
due to expansion and growth into new and existing markets through
our distributors. Alimera also saw an increased sales volume
in the markets where we sell direct.
Operating ExpensesTotal operating expenses were
approximately $13.6 million for the three months ended
December 31, 2019, compared to approximately $13.7 million for
the three months ended December 31, 2018. Total operating expenses
for 2019 were approximately $52.6 million compared to approximately
$52.0 million during the prior year.
Net Income (Loss) Net income for the three months ended
December 31, 2019 was $498,000, compared to a net loss of
approximately/ $1.2 million for the three months ended December 31,
2018. For 2019, net loss totaled approximately $10.4 million
compared to net loss of approximately $16.4 million in
2018.
Basic and diluted net income per share for the three months
ended December 31, 2019 was approximately $0.08 compared to basic
and diluted net loss per share of $(0.27) for the three months
ended December 31, 2018. (The per share amounts in this press
release reflect Alimera’s one-for-15 reverse stock split in
November 2019.)
Basic and diluted net loss per share for 2019 was $(2.19)
compared to basic net income per share for 2018 of $3.74 and
diluted net income per share for 2018 of $3.71. Net income for 2018
was attributable to the gain on the extinguishment of Alimera’s
Series B Convertible Preferred Stock resulting from its exchange in
September 2018 for Series C Convertible Preferred Stock.
Adjusted EBITDA“Adjusted EBITDA,” a non-GAAP financial measure
defined below, was approximately $2.6 million for the three months
ended December 31, 2019, compared to Adjusted EBITDA of
approximately $2.4 million for the three months ended December 31,
2018. For 2019, Adjusted EBITDA was $21,000 compared to an Adjusted
EBITDA loss of approximately $2.0 million for 2018.
Cash and Cash EquivalentsAs of December 31, 2019, Alimera had
cash and cash equivalents of approximately $9.4 million, compared
to $7.9 million at September 30, 2019 and $13.0 million at December
31, 2018.
Definition of Non-GAAP Financial MeasureFor
purposes of this press release, “Adjusted EBITDA” is defined as
earnings before interest, taxes, depreciation, amortization,
stock-based compensation expenses, net unrealized gains and losses
from foreign currency exchange transactions, losses on
extinguishment of debt and severance expenses. Please refer to the
sections of this press release entitled “Non-GAAP Financial
Measure” and “Reconciliation of GAAP Net Loss to Non-GAAP Adjusted
EBITDA.”
Conference Call to Be Held February 27, 2020A
live conference call will be hosted on February 27, 2020 at 9:00am
eastern time by Rick Eiswirth, president and chief executive
officer, and Phil Jones, chief financial officer, to discuss
Alimera’s financial results. Please refer to the information below
for conference call dial-in information and webcast
registration.
Conference date: Thursday February 27, 2020 9:00 AM ET
Conference dial-in: 866-777-2509International dial-in:
412-317-5413Conference Call Name: Alimera Sciences (Nasdaq: ALIM)
Fourth Quarter 2019 and 2019 Financial Results Conference Call
Conference Call Pre-registration: Participants can register
for the conference by navigating to
http://dpregister.com/10139032Please note that registered
participants will receive their dial in number upon registration
and will dial directly into the call without delay.Live Webcast
URL: https://services.choruscall.com/links/alimera200220.html
A replay will be available on Alimera’s
website, www.alimerasciences.com, under
“Investor Relations” one hour following the live call.
Conference Call replay: US Toll Free:
1-877-344-7529International Toll: 1-412-317-0088Canada Toll Free:
855-669-9658Replay Access Code: 10139032End Date: March 12,
2020
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera Sciences is a pharmaceutical company that specializes in
the commercialization and development of prescription ophthalmic
pharmaceuticals. Alimera is presently focused on diseases affecting
the back of the eye, or retina, because these diseases are not well
treated with current therapies and affect millions of people in our
aging populations. For more information, please visit
www.alimerasciences.com.
Non-GAAP Financial Measure
This press release contains a discussion of a non-GAAP financial
measure, as defined in Regulation G promulgated under the
Securities Exchange Act of 1934, as amended. Alimera reports its
financial results in compliance with GAAP but believes that the
non-GAAP measure of Adjusted EBITDA provides useful information to
investors regarding Alimera’s operating performance. Alimera
uses Adjusted EBITDA in the management of its business.
Accordingly, Adjusted EBITDA for the three and twelve months ended
December 31, 2019 and 2018 has been presented in certain instances
excluding items identified in the reconciliations provided in the
table entitled “Reconciliation of GAAP Net Loss to non-GAAP
Adjusted EBITDA.” GAAP net loss is the most directly comparable
GAAP financial measure to Adjusted EBITDA.
Adjusted EBITDA, as presented, may not be comparable to
similarly titled measures reported by other companies because not
all companies may calculate Adjusted EBITDA in an identical manner.
Therefore, Adjusted EBITDA is not necessarily an accurate measure
of comparison between companies.
The presentation of Adjusted EBITDA is not intended to be
considered in isolation or as a substitute for guidance prepared in
accordance with GAAP. The principal limitation of this non-GAAP
financial measure is that it excludes significant elements required
by GAAP to be recorded in Alimera’s financial statements. In
addition, Adjusted EBITDA is subject to inherent limitations as it
reflects the exercise of judgments by management in determining
this non-GAAP financial measure.
Forward Looking Statements
The conference call in which executives of Alimera will discuss
this press release may include “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change these
expectations, and could cause actual results to differ materially
from those projected in these forward-looking statements.
Meaningful factors that could cause actual results to differ
include but are not limited to, lower revenue and a corresponding
decrease in cash due to a reduction in end user demand,
uncertainties associated with COVID-19 – or coronavirus (including
its possible effects on end user demand), unanticipated
competition, regulatory issues, or other unexpected circumstances,
as well as the other factors discussed in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Alimera’s Annual Report on Form
10-K for the year ended December 31, 2018 and Alimera’s
Quarterly Reports on Form 10-Q for the first, second and third
quarters of 2019, which are on file with the Securities and
Exchange Commission (SEC) and available on the SEC’s website at
http://www.sec.gov. Additional factors will also be described in
those sections of Alimera’s Annual Report on Form 10-K for the year
ended December 31, 2019, to be filed with the SEC soon.
For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com
|
For media inquiries: Jules Abraham for
Alimera Sciencesjulesa@coreir.com |
|
|
ALIMERA SCIENCES,
INC.CONSOLIDATED BALANCE
SHEETS(in thousands)
|
|
|
|
|
|
|
|
December 31,2019 |
|
December 31,2018 |
|
(unaudited) |
|
|
CURRENT ASSETS: |
|
|
|
Cash and cash equivalents |
$ |
9,426 |
|
|
$ |
13,043 |
|
Restricted cash |
33 |
|
|
32 |
|
Accounts receivable, net |
19,331 |
|
|
17,259 |
|
Prepaid expenses and other
current assets |
2,565 |
|
|
2,109 |
|
Inventory |
1,390 |
|
|
2,405 |
|
Total current assets |
32,745 |
|
|
34,848 |
|
NON-CURRENT ASSETS: |
|
|
|
Property and equipment,
net |
940 |
|
|
1,355 |
|
Right of use assets, net |
1,107 |
|
|
— |
|
Intangible asset, net |
14,783 |
|
|
16,723 |
|
Deferred tax asset |
734 |
|
|
1,182 |
|
TOTAL ASSETS |
$ |
50,309 |
|
|
$ |
54,108 |
|
CURRENT LIABILITIES: |
|
|
|
Accounts payable |
$ |
7,077 |
|
|
$ |
6,355 |
|
Accrued expenses |
4,716 |
|
|
3,643 |
|
Finance lease obligations |
255 |
|
|
236 |
|
Total current liabilities |
12,048 |
|
|
10,234 |
|
NON-CURRENT LIABILITIES: |
|
|
|
Note payable |
38,658 |
|
|
37,873 |
|
Finance lease obligations —
less current portion |
94 |
|
|
305 |
|
Other non-current
liabilities |
3,954 |
|
|
2,974 |
|
COMMITMENTS AND
CONTINGENCIES |
|
|
|
STOCKHOLDERS’ (DEFICIT)
EQUITY: |
|
|
|
Preferred stock: |
|
|
|
Series A Convertible Preferred
Stock |
19,227 |
|
|
19,227 |
|
Series C Convertible Preferred
Stock |
11,117 |
|
|
11,117 |
|
Common stock |
50 |
|
|
47 |
|
Additional paid-in
capital |
350,117 |
|
|
346,762 |
|
Common stock warrants |
3,707 |
|
|
3,707 |
|
Accumulated deficit |
(387,570 |
) |
|
(377,127 |
) |
Accumulated other
comprehensive loss |
(1,093 |
) |
|
(1,011 |
) |
TOTAL STOCKHOLDERS’ (DEFICIT)
EQUITY |
(4,445 |
) |
|
2,722 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ (DEFICIT) EQUITY |
$ |
50,309 |
|
|
$ |
54,108 |
|
ALIMERA SCIENCES,
INC.CONSOLIDATED STATEMENTS OF
OPERATIONSFOR THE THREE AND TWELVE MONTHS ENDED
DECEMBER 31, 2019 AND 2018(in thousands,
except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember
31, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
|
|
|
|
|
|
|
|
(Unaudited) |
NET REVENUE |
$ |
17,348 |
|
|
$ |
15,114 |
|
|
$ |
53,943 |
|
|
$ |
46,599 |
|
COST OF GOODS SOLD, EXCLUDING
DEPRECIATION AND AMORTIZATION |
(2,273 |
) |
|
(1,325 |
) |
|
(6,626 |
) |
|
(4,308 |
) |
GROSS PROFIT |
15,075 |
|
|
13,789 |
|
|
47,317 |
|
|
42,291 |
|
|
|
|
|
|
|
|
|
RESEARCH, DEVELOPMENT AND
MEDICAL AFFAIRS EXPENSES |
2,670 |
|
|
2,876 |
|
|
10,992 |
|
|
11,274 |
|
GENERAL AND ADMINISTRATIVE
EXPENSES |
3,765 |
|
|
3,995 |
|
|
13,954 |
|
|
14,525 |
|
SALES AND MARKETING
EXPENSES |
6,546 |
|
|
6,142 |
|
|
25,004 |
|
|
23,517 |
|
DEPRECIATION AND
AMORTIZATION |
667 |
|
|
704 |
|
|
2,641 |
|
|
2,645 |
|
OPERATING EXPENSES |
13,648 |
|
|
13,717 |
|
|
52,591 |
|
|
51,961 |
|
NET INCOME (LOSS) FROM
OPERATIONS |
1,427 |
|
|
72 |
|
|
(5,274 |
) |
|
(9,670 |
) |
|
|
|
|
|
|
|
|
INTEREST EXPENSE AND
OTHER |
(1,173 |
) |
|
(1,236 |
) |
|
(4,869 |
) |
|
(4,775 |
) |
UNREALIZED FOREIGN CURRENCY
GAIN (LOSS), NET |
51 |
|
|
(83 |
|
|
(84 |
) |
|
(65 |
|
LOSS ON EARLY EXTINGUISHMENT
OF DEBT |
— |
|
|
— |
|
|
— |
|
|
(1,766 |
) |
NET INCOME (LOSS) BEFORE
TAXES |
305 |
|
|
(1,247 |
) |
|
(10,227 |
) |
|
(16,276 |
) |
PROVISION FOR TAXES |
193 |
|
|
(2 |
) |
|
(216 |
) |
|
(106 |
) |
NET INCOME (LOSS) |
|
498 |
|
|
|
(1,249 |
) |
|
|
(10,443 |
) |
|
|
(16,382 |
) |
GAIN ON EXTINGUISHMENT OF
PREFERRED STOCK |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
38,330 |
|
NET INCOME (LOSS) AVAILABLE TO
STOCKHOLDERS |
$ |
498 |
|
|
$ |
(1,249 |
) |
|
$ |
(10,443 |
) |
|
$ |
21,948 |
|
NET INCOME (LOSS) PER SHARE —
Basic |
$ |
0.08 |
|
|
$ |
(0.27 |
) |
|
$ |
(2.19 |
) |
|
$ |
3.74 |
|
WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING — Basic |
|
4,897,005 |
|
|
|
4,671,041 |
|
|
|
4,770,204 |
|
|
|
4,666,856 |
|
WEIGHTED AVERAGE PARTICIPATING
SHARES – Basic |
|
1,278,170 |
|
|
|
— |
|
|
|
— |
|
|
|
1,199,953 |
|
TOTAL WEIGHTED AVERAGE SHARES
OUTSTANDING — Basic |
6,175,175 |
|
|
4,671,041 |
|
|
4,770,204 |
|
|
5,866,809 |
|
NET INCOME (LOSS) PER SHARE —
Diluted |
$ |
0.08 |
|
|
$ |
(0.27 |
) |
|
$ |
(2.19 |
) |
|
$ |
3.71 |
|
WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING — Diluted |
|
4,920,794 |
|
|
|
4,671,041 |
|
|
|
4,770,204 |
|
|
|
4,715,919 |
|
WEIGHTED AVERAGE PARTICIPATING
AND DILUTIVE SHARES – Diluted |
|
1,278,170 |
|
|
|
— |
|
|
|
— |
|
|
|
1,199,953 |
|
TOTAL WEIGHTED AVERAGE SHARES
OUTSTANDING — Diluted |
6,198,964 |
|
|
4,671,041 |
|
|
4,770,204 |
|
|
5,915,872 |
|
ALIMERA SCIENCES,
INC.REPORTABLE SEGMENT
INFORMATIONFOR THE THREE AND TWELVE MONTHS ENDED
DECEMBER 31, 2019 AND 2018(in
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember 31, 2019 |
Three Months EndedDecember 31,
2018 |
|
|
U.S. |
|
International |
|
Other |
|
Consolidated |
|
U.S. |
|
International |
|
Other |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
NET REVENUE |
$ |
9,505 |
|
|
$ |
7,843 |
|
|
$ |
— |
|
|
$ |
17,348 |
|
|
$ |
8,869 |
|
|
$ |
6,245 |
|
|
$ |
— |
|
|
$ |
15,114 |
|
|
|
COST OF GOODS
SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION |
(993 |
) |
|
(1,280 |
) |
|
— |
|
|
(2,273 |
) |
|
(791 |
) |
|
(534 |
) |
|
— |
|
|
(1,325 |
) |
|
|
GROSS PROFIT |
8,512 |
|
|
6,563 |
|
|
— |
|
|
15,075 |
|
|
8,078 |
|
|
5,711 |
|
|
— |
|
|
13,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RESEARCH,
DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES |
1,314 |
|
|
1,273 |
|
|
83 |
|
|
2,670 |
|
|
1,531 |
|
|
1,139 |
|
|
206 |
|
|
2,876 |
|
|
|
GENERAL AND
ADMINISTRATIVE EXPENSES |
2,334 |
|
|
1,069 |
|
|
362 |
|
|
3,765 |
|
|
1,937 |
|
|
843 |
|
|
1,215 |
|
|
3,995 |
|
|
|
SALES AND
MARKETING EXPENSES |
4,830 |
|
|
1,609 |
|
|
107 |
|
|
6,546 |
|
|
4,142 |
|
|
1,783 |
|
|
217 |
|
|
6,142 |
|
|
|
DEPRECIATION AND
AMORTIZATION |
— |
|
|
— |
|
|
667 |
|
|
667 |
|
|
— |
|
|
— |
|
|
704 |
|
|
704 |
|
|
|
OPERATING
EXPENSES |
8,478 |
|
|
3,951 |
|
|
1,219 |
|
|
13,648 |
|
|
7,610 |
|
|
3,765 |
|
|
2,342 |
|
|
13,717 |
|
|
|
SEGMENT INCOME
(LOSS) FROM OPERATIONS |
34 |
|
|
2,612 |
|
|
(1,219 |
) |
|
1,427 |
|
|
468 |
|
|
1,946 |
|
|
(2,342 |
) |
|
72 |
|
|
|
OTHER INCOME AND
EXPENSES, NET |
— |
|
|
— |
|
|
(1,122 |
) |
|
(1,122 |
) |
|
— |
|
|
— |
|
|
(1,319 |
) |
|
(1,319 |
) |
|
|
NET INCOME (LOSS)
BEFORE TAXES |
|
|
|
|
|
|
$ |
305 |
|
|
|
|
|
|
|
|
$ |
(1,247 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months EndedDecember 31,
2019 |
|
Twelve Months EndedDecember 31,
2018 |
|
|
U.S. |
|
International |
|
Other |
|
Consolidated |
|
U.S. |
|
International |
|
Other |
|
Consolidated |
|
|
(unaudited) |
NET REVENUE |
$ |
32,283 |
|
|
$ |
21,660 |
|
|
$ |
— |
|
|
$ |
53,943 |
|
|
$ |
31,966 |
|
|
$ |
14,633 |
|
|
$ |
— |
|
|
$ |
46,599 |
|
COST OF GOODS
SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION |
(3,487 |
) |
|
(3,139 |
) |
|
— |
|
|
(6,626 |
) |
|
(2,875 |
) |
|
(1,433 |
) |
|
— |
|
|
(4,308 |
) |
GROSS PROFIT |
28,796 |
|
|
18,521 |
|
|
— |
|
|
47,317 |
|
|
29,091 |
|
|
13,200 |
|
|
— |
|
|
42,291 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RESEARCH,
DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES |
5,943 |
|
|
4,634 |
|
|
415 |
|
|
10,992 |
|
|
6,457 |
|
|
3,946 |
|
|
871 |
|
|
11,274 |
|
GENERAL AND
ADMINISTRATIVE EXPENSES |
8,449 |
|
|
3,944 |
|
|
1,561 |
|
|
13,954 |
|
|
8,147 |
|
|
3,259 |
|
|
3,119 |
|
|
14,525 |
|
SALES AND
MARKETING EXPENSES |
17,591 |
|
|
6,933 |
|
|
480 |
|
|
25,004 |
|
|
16,569 |
|
|
5,910 |
|
|
1,038 |
|
|
23,517 |
|
DEPRECIATION AND
AMORTIZATION |
— |
|
|
— |
|
|
2,641 |
|
|
2,641 |
|
|
— |
|
|
— |
|
|
2,645 |
|
|
2,645 |
|
OPERATING
EXPENSES |
31,983 |
|
|
15,511 |
|
|
5,097 |
|
|
52,591 |
|
|
31,173 |
|
|
13,115 |
|
|
7,673 |
|
|
51,961 |
|
SEGMENT (LOSS)
INCOME FROM OPERATIONS |
(3,187 |
) |
|
3,010 |
|
|
(5,097 |
) |
|
(5,274 |
) |
|
(2,082 |
) |
|
85 |
|
|
(7,673 |
) |
|
(9,670 |
) |
OTHER INCOME AND
EXPENSES, NET |
— |
|
|
— |
|
|
(4,953 |
) |
|
(4,953 |
) |
|
— |
|
|
— |
|
|
(6,606 |
) |
|
(6,606 |
) |
NET LOSS BEFORE
TAXES |
|
|
|
|
|
|
$ |
(10,227 |
) |
|
|
|
|
|
|
|
$ |
(16,276 |
) |
RECONCILIATION OF GAAP MEASURES TO
NON-GAAP ADJUSTED MEASURESGAAP NET LOSS TO
NON-GAAP ADJUSTED EBITDA(in
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
Twelve Months EndedDecember
31, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
|
|
|
|
|
|
|
|
(Unaudited) |
GAAP NET INCOME (LOSS) |
$ |
498 |
|
|
|
$ |
(1,249 |
) |
|
|
$ |
(10,443 |
) |
|
|
$ |
(16,382 |
) |
Adjustments to net loss: |
|
|
|
|
|
|
|
Interest expense and
other |
1,173 |
|
|
|
1,236 |
|
|
|
4,869 |
|
|
|
4,775 |
|
Provision for taxes |
(193 |
) |
|
|
2 |
|
|
|
216 |
|
|
|
106 |
|
Depreciation and
amortization |
667 |
|
|
|
704 |
|
|
|
2,641 |
|
|
|
2,645 |
|
Stock-based compensation
expenses |
553 |
|
|
|
1,021 |
|
|
|
2,456 |
|
|
|
4,411 |
|
Unrealized foreign currency
exchange (gains) losses |
(51 |
) |
|
|
83 |
|
|
|
84 |
|
|
|
65 |
|
Loss on early extinguishment
of debt |
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,766 |
|
Severance expenses |
— |
|
|
|
617 |
|
|
|
198 |
|
|
|
617 |
|
NON-GAAP ADJUSTED EBITDA |
$ |
2,647 |
|
|
|
$ |
2,414 |
|
|
|
$ |
21 |
|
|
|
$ |
(1,997 |
) |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024